Whether or not it is sold OTC, it’s not a drug. The competition consists of the OTC supplements from such companies as BOL. It has nothing whatsoever to do with Lucentis.
You say 'patent medicine', I say 'drug'. What matters is:
a) Is it by prescription?
b) Is it paid for by insurance?
c) Is it patent protected?
d) Is it efficacious vs competitive treatment?
If it meets these criteria than it has pricing power. And Lucentis is a comparable entity from the only perspective that matters on a stock board.
PS Of course if it is sold as OTC then you are right; comparison to Lucentis is somewhat misleading.
Market Data 
Markets 
AI
